Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
The number and variety of test interfaces, coupled with increased packaging complexity, are adding a slew of new challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results